in less than 90 days . TIC TOC TIC .....,,,,.....Sure is a lot of info and news coming from management , must be a prolonged quiet period.
in QFOR.s space is the ability to make money with sales. After listening to CC call I am left with the feeling that QFOR will be doing the heavy lifting of data gathering and organizing data but not monatising anything for years to come. Having seen what a smart management team did with a company like salesforce, making money while setting up programs and process.s for companies , Qfor seems to be doing the work for peanuts/gratis and expecting to get paid down the road. Recurring revenue streams are good but QFOR is doing all the heavy lifting and I question the ability to protect future revenue streams. From the contracts they have reported and the lead times they are claiming to implement programs and to start making money it appears that the contracts expire before they can monatise anything of substance. Another question is will big companies be comfortable with all of their confidential info being sent to some back water area of India or will they want most of their proprietary info handled in U.S.A. I know a lot of current government quotes/ contracts are not allowing outsourcing leaving the U.S.
I have been following QFOR for awhile now and every call seems to be something new that pushes off revenue sales growth and recurring revenue growth. We know the space is attractive but my question is can QFOR.s management play with the big boys or are they fast becoming a wannabe. It is strange that things have been improving, businesswise according to management, for the last few quarters yet the stock price , a reflection of investor confidence , has been going down.
I know , I have been in since IPO and have had to buy more than I planned averaging down. The fact is Sharma has a ton of $$$$$ riding on CGIX and a ton of incentive options , etc. and he still bought on the open market with Poppajohn.
An aside nobody is talking about is the reliance that some big Pharma companies are building on CGIX platforms. It's possible CGIX goes cash flow positive faster than expected.
in fairness it was an open market transaction. He has a lot of his comp tied up with the price of cgix stock if I remember correctly. Management could use a marketing/financial guy , IMO. But if Poppajohn still supports lets see were we go.
on the open market. According to SEC filings between 3/15 and 3/16 Poppajohn bought 100k shares and Sharma bought 1k on the open market. A start and a much needed vote of confidence in my opinion.
It's tax time and I get to revisit mela and reap my tax loss adjustment. The message board is still populated with the same personalities and management continues to grow more inept with each passing year. It's reassuring to know in this ever changing world that some things never change. My question regarding mela or strata or whatever now is " what happens first , do they go out of business or will my tax loss benefit play out?
Health and Happiness to all.
FDA approval of surgibot , I think TRXC will announce the sale of a European machine first. IMO , FDA approval is big but the creation of a revenue stream wouldbe/is of greater importance right now. Either way the next couple of weeks should be interesting.
Don't they have to have a signed contract before they can report one? If they have one and don't report it they are in breach of an SEC rule.
new contract signings for the quarter? Qfor could use a marketing/sales guru. Thought we would have heard something by now regarding all the potential new contracts that management has talked about over the past few quarters/YEARS NOW. This company is in desperate need of a catalyst soon before the market and the street pass it by. Very curious about the recurring revenues they report this quarter. This company really needs something positive soon IMO .
sometimes our questions answer themselves. Just needs to get cash flowing, recurring revenues is the hidden gem to this stock. Until then investors will continue to fear dilution.
the atm is shares not dollars. if they sell at $1PS they get $43 million , if they sell at $100PS they get $430 million. The dilution is to the shareholder %. If the float is 100 and they add 43 to the float the dilution is 43%. if you owned 1 share prior to sale you owned 1% of float after the sale you will own .6% of the float , hence dilution.
the ATM is 43 million shares not dollars if I remember correctly so the dilution will be constant irregardless of pps. I agree the preference is to let the pps rise prior to sales.
I will answer this way, robotic surgery is the future and TRXC is in a great position presently to capitalize greatly. Whether the management team can take advantage of their current position is what we are currently speculating on. I have been building a position for the past year now.
I seem to recall a year or so back management discussing a reverse split if the pps didn't start trading a more realistic price level. IMO QFOR is trading at a discount due to past management problems. If you have followed QFOR for the past couple of years my past posts reflect my thoughts on what should/could be done by management.
11000 shares trade, a total dollar value of less than $4400. dollars, resulting in a 30+% pps price swing. When will management address this problem ? When will we hear anything regarding new sales ? QFOR could sure use a smart , aggressive sales/marketing individual.
Do not forget OPKO and the Dr. Frost connection. Really, when approval is granted by the FDA , the market value of TRXC should be at least $ 1 billion $. a far cry from its present valuation. Enjoy the ride.
as the smart money starts/continues to accumulate during 2016. FDA approval for Surgibot in coming weeks. Sales in Europe will start in coming quarters with FDA / U.S. filing in late 2016 for European machine. Will need to raise capital but will have an FDA approved device for sale in U.S. and sales starting to ramp in Europe, raising money will not be a problem. IF all goes as planned and they produce any sales in 2016, the patents alone will make this a 10-20 bagger in the coming year or so, in my opinion. Google , J&J , Stryker or a host of other Medical device companies will pay a $ Billion $ or $ two$ for approved devices and patents.